1. France Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Ipsen S.A.

Ipsen S.A.

IPSEF
Ipsen S.A.US flagOther OTC
113.13
USD
- -
- -
9.36BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
15.44
16.23
18.48
20.3
24.37
28.33
32.41
32.38
33.26
38.3
39.97
43.2
- -
Basic EPS, GAAP
1.84
1.87
2.31
2.74
3.3
4.7
-0.61
6.61
7.82
7.87
7.79
4.18
- -
Free Cash Flow per Basic Share
1.51
1.97
1.8
-0.66
2.21
3.42
4.18
7.6
5.75
8.72
8.18
1.61
- -
Dividend per Share
0.8
0.8
0.85
0.85
0.85
1
1
1
1
1.2
1.2
1.2
- -
Book Value per Share
2.85
2.88
3.32
3.76
4.31
5.71
0.4
7.62
8.84
8.89
8.8
5.19
- -
Tangible Book Value per Share
6.24
7.1
8.76
7.59
2.62
5.26
-3.16
5.06
9.01
14.29
5.82
11.65
- -
Basic Weighted Avg Shares
83
82
82
82
83
83
83
83
83
82
83
83
- -
Sales/Revenue/Turnover
1,282
1,332
1,520
1,671
2,012
2,348
2,693
2,686
2,749
3,156
3,306
3,574
3,929
Operating Margin (%)
17.42
18.86
20.73
20.91
19.94
23.69
24.62
26.96
31.05
27.6
18.49
19.25
24.05
Depreciation Expense
26
50
44
39
106
143
161
235
246
336
88
706
625
Net Income, GAAP
152
154
190
226
272
390
-51
548
647
649
644
346
444
Effective Tax Rate (%)
29.43
26.08
20.99
24.68
27.35
21.88
- -
- -
20.06
15.9
17.89
17.35
23.09
Profit Margin (%)
11.9
11.52
12.49
13.52
13.54
16.59
-1.88
20.4
23.52
20.55
19.49
9.68
11.29
Working Capital
226
261
348
489
75
226
-106
366
725
1,062
272
516
1,384
LT Debt
- -
12
- -
297
298
298
696
639
658
582
337
390
832
Total Equity
974
1,068
1,226
1,362
1,536
1,843
1,753
2,134
2,738
3,343
3,824
4,182
4,337
Return on Invested Capital (%)
16.3
17.53
20.87
17.76
16.1
20.92
- -
- -
20.87
19.52
12.07
12.66
14.63
Return on Capital (%)
99.8
61.73
69.39
50.72
41.59
51.67
- -
- -
45.4
48.74
55
38.74
42.32
Return on Common Equity (%)
104.09
64.89
74.54
77.55
81.83
93.93
-20.02
164.84
94.93
88.68
88.24
59.75
92.69

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.86%
15.57%
3.71%
Free Cash Flow
3.81%
89.84%
508.8%
Net Income, GAAP
-121.18%
-0.09%
28.22%
Sales/Revenue/Turnover
10.14%
7.99%
9.92%
Total Cash Common Dividend
- -
- -
16.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3,306
2024
- -
- -
- -
- -
3,574
2025
- -
- -
- -
- -
3,929

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
7.79
2024
- -
- -
- -
- -
4.18
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.2
2024
- -
- -
- -
- -
1.2
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David Loew
Full Time Employees
5,358
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
65 Quai Georges Gorse Boulogne-Billancourt France 92100
IPO Date
Sep 21, 2009
Website
ipsen.com
Similar Companies
Lumiera Health Inc. (NHPHF)
Probiotec Limited (PBP.AX)
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF)
Nippon Chemiphar Co., Ltd. (4539.T)
Lee's Pharmaceutical Holdings Limited (0950.HK)
Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ)
Business
Ipsen S.A. (IPN.PA; IPSEY) is a global biopharmaceutical company focused on developing and commercializing innovative medicines in oncology, rare diseases, and neuroscience; its core products include Somatuline (lanreotide) and Cabometyx (cabozantinib) for neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma, and other cancers; Dysport (abobotulinumtoxinA) for spasticity, cervical dystonia, and aesthetics; and Bylvay (odevixibat) and Iqirvo (elafibranor) for rare liver diseases such as progressive familial intrahepatic cholestasis (PFIC) and primary biliary cholangitis (PBC); the company also advances therapies for growth disorders, rare bone diseases, rare neurogenetic disorders, and neurological conditions. Founded in 1929 as Laboratoires Beaufour and headquartered in Paris, France, Ipsen operates in over 88 countries with approximately 5,000 employees and emphasizes partnerships to build its pipeline, targeting patients with high unmet medical needs. Recent developments include the October 2025 announcement of a definitive agreement to acquire ImCheck Therapeutics for up to €1 billion to expand its oncology pipeline with ICT01, a first-in-class gamma delta T-cell activator for hematological malignancies; expansion of partnerships with Marengo Therapeutics (June 2024) and Skyhawk Therapeutics (April 2024) in oncology and neuroscience; positive Phase II LANTIC trial results for IPN10200 in aesthetics (September 2025), enabling Phase III initiation; regulatory approvals for Bylvay in Japan (September 2025) and Cabometyx in the EU for advanced neuroendocrine tumors (July 2025); and strong nine-month 2025 sales growth of 12.1% at constant exchange rates across all therapeutic areas, prompting an upgraded full-year guidance.

Company News

APIChat